Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tuberculosis treatment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    283 result(s) found for: Tuberculosis treatment. Displaying page 2 of 15.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-003301-22 Sponsor Protocol Number: AC-R6 Start Date*: 2021-10-05
    Sponsor Name:Archivel Farma S.L.
    Full Title: A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB (CONSTAN)
    Medical condition: Pulmonary Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000513-39 Sponsor Protocol Number: LIN-interaction-01 Start Date*: 2011-07-27
    Sponsor Name:University Medical Center Groningen
    Full Title: The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients
    Medical condition: Multidrug-resistant and extensively drug-resistant tubeculosis (MDR/XDR-TB)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10043148 TB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004462-40 Sponsor Protocol Number: TMC207-TiDP13-C208 Start Date*: 2007-12-20
    Sponsor Name:Tibotec BVBA
    Full Title: A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection...
    Medical condition: Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044755 Tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-005492-13 Sponsor Protocol Number: TMC207TBC1002 Start Date*: 2013-03-26
    Sponsor Name:Janssen infectious diseases BVBA
    Full Title: A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatri...
    Medical condition: Multi-drug resistant tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001184-24 Sponsor Protocol Number: SXT8469 Start Date*: 2013-08-20
    Sponsor Name:UMCG
    Full Title: Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients with Tuberculosis
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002000-31 Sponsor Protocol Number: FSJD-ISON-2016 Start Date*: 2016-09-21
    Sponsor Name:FUNDACIÓ SANT JOAN DE DÉU
    Full Title: Open clinical trial phase IIa to study the isoniazid suspension absoption of 10mg/ml for the tuberculosis infection treatment in patients under the age of 6
    Medical condition: tuberculosis infection in patients under the age of 6
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000750-21 Sponsor Protocol Number: 12/0426 Start Date*: 2013-12-18
    Sponsor Name:University College London
    Full Title: The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid for latent tuberculosis infection (LTBI)
    Medical condition: Latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005664-88 Sponsor Protocol Number: HB996 Start Date*: 2006-12-08
    Sponsor Name:University of Oxford
    Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ...
    Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004444-29 Sponsor Protocol Number: RID-TB:Treat Start Date*: 2020-11-25
    Sponsor Name:University College London
    Full Title: An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completio...
    Medical condition: Latent Tuberculosis infection (LTBI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001820-36 Sponsor Protocol Number: 114886 Start Date*: 2012-10-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine GSK 692342 when administered to ...
    Medical condition: Vaccination against tuberculosis (TB) in adults aged 18 to 59 years with TB disease.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10045023 Tuberculosis prophylaxis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023189-27 Sponsor Protocol Number: RG-10-179 Start Date*: 2011-01-20
    Sponsor Name:University of Birmingham
    Full Title: The pharmacogenetics of vitamin D response in tuberculosis
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003567-20 Sponsor Protocol Number: A101A Start Date*: 2017-04-21
    Sponsor Name:Dept of Infectious Diseases, Aarhus University Hospital
    Full Title: A randomised controlled trial of a 12-dose rifapentine and isoniazid (RPT+INH) regimen using direct observed therapy (DOT) versus 6 months of daily isoniazid for latent tuberculosis infection (LTBI...
    Medical condition: Latent tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005142-12 Sponsor Protocol Number: TMC207-C203 Start Date*: 2005-06-25
    Sponsor Name:Tibotec Pharmaceuticals Limited
    Full Title: An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of...
    Medical condition: Tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003312-29 Sponsor Protocol Number: UITB Estudio 28 Start Date*: 2006-05-17
    Sponsor Name:TB Investigation Unit of Barcelona
    Full Title: Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28
    Medical condition: To compare two treatments for pulmonary tuberculosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003446-45 Sponsor Protocol Number: TBTCS31/A5349 Start Date*: 2016-02-25
    Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona
    Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial
    Medical condition: Pulmonary tuberculosis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003146-36 Sponsor Protocol Number: RIAlta-1 Start Date*: 2023-11-15
    Sponsor Name:Vall d'Hebron Research Institute (VHIR)
    Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis
    Medical condition: Pulmonary and extrapulmonary tuberculosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003721-25 Sponsor Protocol Number: High-shortRP Start Date*: 2020-02-03
    Sponsor Name:Region Östergötland
    Full Title: Randomized prospective phase II clinical trial investigating pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in an shortened tuberculosis treatment compared to st...
    Medical condition: Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10044755 Tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002094-58 Sponsor Protocol Number: UITB-TBTC-Estudio33 Start Date*: 2012-10-26
    Sponsor Name:Unidad de Investigación en Tuberculosis de Barcelona (UITB)
    Full Title: An evaluation of adherence to LTBI treatment with 12 doses of once weekly rifapentine and isoniazid given as self-administered versus directly-observed therapy: iAdhere
    Medical condition: Adherence study in subjects with Latent Tuberculosis Infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000358-13 Sponsor Protocol Number: A3921187 Start Date*: 2014-12-04
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATO...
    Medical condition: Moderately to severely active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) LT (Completed) LV (Completed) GB (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Completed) DE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001173-69 Sponsor Protocol Number: 126496 Start Date*: 2020-10-22
    Sponsor Name:Pernille Ravn
    Full Title: Impact of LTBI treatment on glucose tolerance and chronic inflammation
    Medical condition: latent tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 15 06:56:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA